BioNTech SE (BNTX) has released an update.
Pfizer and BioNTech have announced FDA approval and emergency use authorization for their Omicron KP.2-adapted COVID-19 vaccine, aimed at the upcoming 2024-2025 fall and winter season in the U.S. The vaccine is recommended for individuals 6 months and older and is set to be distributed in pharmacies, hospitals, and clinics across the country. This approval comes as a proactive measure against the predicted rise in COVID-19 cases and is based on extensive clinical evidence demonstrating its safety and enhanced response against current Omicron sublineages.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
